design
retrospect
observ
studi
set
two
medic
center
taiwan
patient
fortyfour
patient
sar
receiv
ribavirin
patient
sar
receiv
ribavirin
mean
peak
creactiv
protein
lactat
dehydrogenas
level
higher
sar
patient
receiv
ribavirin
therapi
sar
patient
receiv
ribavirin
therapi
mortal
also
higher
differ
statist
signific
multivari
analysi
hemoglobin
level
independ
prognost
correl
hypoxemia
mortal
odd
ratio
confid
interv
p
hemoglobin
began
decreas
two
third
sar
patient
patient
receiv
ribavirin
day
therapi
antivir
drug
start
patient
drop
hemoglobin
level
gdl
significantli
higher
mortal
rate
patient
hypoxemia
develop
one
third
sar
patient
patient
receiv
ribavirin
anem
hypoxem
patient
drop
hemoglobin
gdl
patient
requir
blood
transfus
mean
slope
hemoglobin
decreas
significantli
steeper
p
hypoxem
patient
sar
receiv
ribavirin
nonhypoxem
patient
sar
receiv
ribavirin
one
seven
sar
patient
receiv
ribavirin
becam
anem
individu
hypoxem
eventu
hypoxem
anem
sar
patient
receiv
ribavirin
die
combin
hypoxia
anemia
thu
significantli
associ
higher
mortal
p
conclus
hypoxia
combin
anemia
increas
risk
death
sar
patient
unless
ribavirin
shown
effect
sarscoronaviru
risk
anemia
pose
drug
argu
use
sar
patient
chest
report
countri
death
attribut
sar
face
rapidli
spread
novel
infect
lethal
substanti
number
patient
varieti
treatment
tri
ribavirin
watersolubl
synthet
guanosin
analog
broadspectrum
antivir
activ
dna
rna
virus
indic
treatment
respiratori
syncyti
viru
infant
hepat
c
combin
interferon
hemorrhag
fever
influenza
b
infect
empir
use
ribavirin
corticosteroid
therefor
initi
recommend
treatment
sar
mani
hospit
manag
earliest
wave
sar
outbreak
howev
benefit
therapi
still
debat
advers
effect
ae
ribavirin
report
extens
literatur
includ
dosedepend
anemia
hemolysi
bone
marrow
suppress
arrhythmia
elev
lactat
pyruv
level
hypocalcemia
hypomagnesemia
report
side
effect
includ
exampl
chest
pain
dizzi
hyperuricemia
hyperbilirubinemia
interstiti
pneumon
decreas
wbc
count
thrombocytopenia
common
ae
revers
dosedepend
timedepend
anemia
especi
drug
given
dose
g
daili
day
aim
studi
evalu
outcom
sar
patient
treat
ribavirin
particularli
relat
ribavirininduc
anemia
order
provid
basi
assess
risk
benefit
drug
retrospect
review
record
patient
confirm
sar
infect
manag
two
medic
center
taiwan
april
june
outbreak
taiwan
patient
suspect
sar
randomli
sent
design
hospit
depart
health
therefor
particular
bia
patient
seen
standard
treatment
protocol
includ
ribavirin
recommend
taiwan
center
diseas
control
use
patient
mackay
memori
hospit
hospit
anoth
seven
patient
chang
gung
memori
hospit
hospit
c
receiv
similar
treatment
except
ribavirin
allow
comparison
patient
treat
without
ribavirin
fig
patient
confirm
sarscov
infect
reversetranscriptas
polymeras
chain
reaction
realtim
polymeras
chain
reaction
throat
nasopharyng
swab
least
two
differ
occas
studi
popul
thu
consist
sar
patient
receiv
ribavirin
sar
patient
receiv
ribavirin
data
collect
record
includ
symptom
underli
diseas
physic
find
result
serial
chest
radiograph
satur
monitor
laboratori
data
laboratori
test
consist
consecut
hematolog
examin
includ
hemoglobin
concentr
absolut
lymphocyt
count
platelet
count
serum
biochemistri
includ
measur
creatinin
aspart
aminotransferas
alanin
aminotransferas
creatin
phosphokinas
lactat
dehydrogenas
creactiv
protein
level
order
defin
chronolog
progress
diseas
first
day
document
temperatur
design
fever
day
fd
effect
ribavirin
evalu
assess
patient
respons
includ
symptom
sign
chest
radiograph
pattern
patient
receiv
least
day
ribavirin
therapi
evalu
drug
safeti
anemia
defin
decreas
hemoglobin
level
mgl
hypoxemia
defin
one
follow
condit
pao
mm
hg
arteri
oxygen
satur
ratio
pao
fraction
inspir
oxygen
mm
hg
need
mechan
ventil
order
evalu
relat
among
ribavirin
hypoxemia
outcom
sar
patient
also
assign
one
follow
two
group
base
presenc
hypoxemia
sarsribavirinnonhypoxem
srnh
n
sarsribavirinhypoxem
srh
n
outcom
group
compar
fig
soon
diagnosi
pneumonia
sar
consid
patient
isol
treat
iv
cephalosporin
eg
ceftriaxon
g
cefepim
g
oral
fluoroquinolon
eg
levofloxacin
mg
daili
moxifloxacin
mg
daili
clinic
present
fulfil
case
definit
sar
patient
admit
negativepressur
isol
room
sar
treatment
protocol
begun
fig
protocol
use
hospit
consist
oral
ribavirin
mg
stat
mg
daili
patient
weigh
kg
mg
patient
weight
kg
day
dose
adjust
renal
dysfunct
fall
hemoglobin
patient
condit
improv
follow
day
therapi
ribavirin
corticosteroid
ad
start
iv
methylprednisolon
mgkg
day
day
follow
oral
prednisolon
taper
day
fever
persist
lung
infiltr
oxygen
worsen
day
therapi
methylprednisolon
patient
given
puls
methylprednisolon
mg
twice
daili
day
andor
iv
ig
mgkg
day
oxygen
therapi
administ
nasal
cannula
nonrebreath
mask
mechan
ventil
use
maintain
puls
oximetr
satur
pao
mm
hg
protocol
use
hospit
c
similar
except
ribavirin
therapi
includ
treatment
data
express
mean
sd
univari
analysi
conduct
pearson
test
categor
variabl
mannwhitney
u
test
continu
variabl
associ
durat
ribavirin
therapi
chang
hemoglobin
level
identifi
linear
regress
analysi
surviv
curv
obtain
kaplanmei
estim
compar
logrank
test
twosid
p
valu
multivari
logist
regress
backward
stepwis
analysi
perform
identifi
independ
risk
factor
associ
develop
hypoxemia
mortal
trend
hemoglobin
chang
compar
srnh
srh
group
student
test
result
consid
statist
signific
p
valu
differ
group
tabul
analyz
use
statist
softwar
packag
spss
version
spss
chicago
il
mean
age
patient
year
malefemal
ratio
sar
patient
receiv
ribavirin
sought
medic
care
mean
fd
sar
patient
receiv
ribavirin
sought
medic
care
mean
fd
demograph
data
initi
laboratori
result
group
shown
tabl
except
higher
aspart
aminotransferas
level
sar
patient
receiv
ribavirin
therapi
compar
sar
patient
receiv
ribavirin
therapi
p
slightli
differ
lactat
dehydrogenas
level
p
signific
differ
baselin
characterist
two
group
fall
hemoglobin
level
common
sar
patient
patient
one
seven
sar
patient
receiv
ribavirin
becam
anem
significantli
fewer
among
patient
receiv
ribavirin
fig
hospit
admiss
sar
patient
receiv
ribavirin
patient
sar
patient
receiv
ribavirin
patient
abnorm
chest
radiograph
find
sar
patient
receiv
ribavirin
patient
alreadi
multifoc
infiltr
hospit
admiss
patient
time
cours
radiograph
abnorm
could
ascertain
patient
unifoc
airspac
infiltr
patient
multifoc
infiltr
appear
fd
sar
patient
receiv
ribavirin
four
six
patient
unifoc
infiltr
two
six
patient
multifoc
infiltr
appear
fd
respect
eventu
sar
patient
studi
pulmonari
infiltr
mostli
diffus
progress
fd
hypoxemia
develop
sar
patient
patient
receiv
ribavirin
mean
fd
one
seven
patient
sar
receiv
ribavirin
hypoxemia
develop
fd
p
fig
mean
peak
creactiv
protein
lactat
dehydrogenas
level
higher
sar
patient
receiv
ribavirin
therapi
sar
patient
receiv
ribavirin
therapi
tabl
mortal
also
higher
differ
statist
signific
fig
sar
patient
receiv
ribavirin
first
look
variabl
associ
hypoxemia
mortal
univari
analysi
tabl
found
associ
p
valu
univari
analysi
analyz
associ
use
multivari
logist
regress
multivari
analysi
hemoglobin
level
significantli
correl
hypoxemia
death
odd
ratio
confid
interv
p
hospit
ribavirin
administ
begin
mean
fd
total
mean
durat
day
anemia
patient
common
ae
observ
sar
patient
hospit
sixteen
patient
drop
hemoglobin
level
gdl
patient
significantli
higher
mortal
patient
great
drop
hemoglobin
figur
show
surviv
curv
sar
patient
without
drop
hemoglobin
gdl
evalu
associ
ribavirin
administr
fall
hemoglobin
level
hypoxemia
chang
hemoglobin
level
record
fig
ribavirin
therapi
begun
mean
hemoglobin
concentr
srh
srnh
group
normal
mean
hemoglobin
concentr
srh
group
significantli
lower
group
srh
group
hemoglobin
level
began
decreas
day
start
ribavirin
therapi
reach
nadir
day
start
therapi
return
normal
week
discontinu
drug
mean
decreas
hemoglobin
level
gdl
patient
srh
group
becam
anem
accord
definit
patient
requir
blood
transfus
linear
statist
correl
hemoglobin
surviv
group
patient
r
p
fig
srnh
group
hemoglobin
level
drop
somewhat
mean
remain
lower
limit
normal
patient
group
becam
anem
accord
definit
srh
group
mean
slope
hemoglobin
decreas
significantli
steeper
vs
p
fig
anemia
significantli
common
p
fig
srnh
group
interestingli
patient
initi
treat
ribavirin
subsequ
exclud
sar
also
develop
anemia
moreov
differ
incid
anemia
nonsar
sar
patient
patient
vs
patient
p
link
even
stronger
relationship
use
ribavirin
develop
anemia
describ
rel
poor
outcom
sar
patient
receiv
ribavirin
anemia
hypoxemia
fall
hemoglobin
level
common
side
effect
ribavirin
also
observ
patient
varieti
sever
diseas
includ
sar
found
sar
patient
patient
receiv
ribavirin
develop
decreas
hemoglobin
level
compar
sar
patient
patient
receiv
ribavirin
p
also
found
patient
initi
suspect
sar
therefor
treat
ribavirin
later
prove
caus
pneumonia
approxim
half
patient
becam
anem
hospi
ribavirin
begun
mean
hemoglobin
concentr
srh
srnh
group
normal
mean
srh
group
significantli
lower
srnh
group
srh
group
hemoglobin
level
began
decreas
day
start
ribavirin
therapi
reach
nadir
day
start
therapi
return
normal
week
discontinu
therapi
wwwchestjournalorg
chest
juli
taliz
hypoxemia
less
common
patient
receiv
ribavirin
patient
receiv
ribavirin
becom
hypoxem
hospit
perhap
strike
find
among
patient
receiv
ribavirin
number
death
patient
hypoxem
anem
patient
compar
among
patient
hypoxem
patient
half
patient
latter
group
patient
anem
although
mean
hemoglobin
level
nonhypoxem
group
whole
remain
normal
nearnorm
throughout
hospit
one
seven
patient
receiv
ribavirin
becam
hypoxem
patient
anem
fig
possibl
prove
extent
anemia
observ
seri
caus
ribavirin
howev
reason
assum
drug
known
caus
anemia
may
contribut
part
drop
hemoglobin
symptom
sar
develop
sequenti
begin
fever
cough
diarrhea
eventu
dyspnea
pulmonari
infiltr
appear
chest
radiograph
patient
averag
fd
accompani
respiratori
symptom
ribavirin
therapi
begun
mean
fd
given
total
day
two
third
patient
patient
sar
decreas
hemoglobin
begin
day
ribavirin
start
fd
coincid
progress
patient
diffus
pulmonari
infiltr
hypoxemia
mean
fd
presum
part
natur
cours
sar
thu
reduc
oxygencarri
capac
like
relat
least
part
treatment
ribavirin
superimpos
hypoxemia
secondari
sarscovinduc
lung
patholog
danger
combin
associ
higher
risk
death
pharmacotherapi
sar
outbreak
divers
base
larg
anecdot
evid
addit
ribavirin
oseltamivir
ritonavirlopinavir
kaletra
abbott
laboratori
abbott
park
il
tri
physician
hong
kong
recommend
iv
ribavirin
mg
daili
least
day
follow
oral
treatment
mg
daili
continu
iv
ribavirin
therapi
dose
mgkg
everi
h
day
canada
patient
receiv
load
dose
g
iv
follow
g
iv
everi
h
day
figur
proport
patient
surviv
relat
hemoglobin
concentr
linear
statist
correl
hemoglobin
level
surviv
srh
group
r
p
decreas
hemoglobin
level
patient
superimpos
hypoxemia
secondari
sarscovinduc
lung
patholog
higher
risk
death
mg
everi
h
day
howev
cours
outbreak
patient
treat
ribavirin
appear
wors
outcom
concern
side
effect
lack
evid
efficaci
sarscov
either
vitro
anecdot
health
canada
stop
provid
ribavirin
treatment
sar
sever
month
outbreak
use
lower
dose
ribavirin
treatment
protocol
howev
patient
clinic
progress
sar
ribavirin
therapi
begun
given
addit
therapi
steroid
iv
ig
accord
protocol
observ
evid
patient
support
role
ribavirin
treat
sar
ribavirininduc
anemia
appear
result
inhibit
late
stage
erythrocyt
matur
bone
marrow
hemolysi
erythrocyt
also
evid
ribavirininduc
oxid
damag
erythrocyt
membran
may
caus
erythrophagocyt
extravascular
destruct
ribavirin
shown
lower
level
adenosin
triphosph
glucos
erythrocyt
might
addit
factor
affect
oxygencarri
capac
reason
poor
outcom
sar
patient
appear
multifactori
risk
factor
propos
variou
investig
includ
genet
polymorph
initi
viral
load
older
age
comorbid
especi
diabet
mellitu
heart
diseas
research
critic
care
identifi
anemia
hypoxia
import
risk
factor
mortal
anem
patient
pulmonari
diseas
develop
dyspnea
tachypnea
sever
hypoxia
easili
patient
normal
hemoglobin
level
global
tissu
hypoxia
independ
risk
factor
microcirculatori
failur
organ
dysfunct
poor
outcom
death
earli
goaldirect
therapi
carri
maintain
central
venou
oxygen
satur
blood
transfus
provid
supplement
shown
decreas
mortal
significantli
critic
ill
patient
srh
patient
hypoxemia
develop
coincident
fall
hemoglobin
level
perhap
surpris
wors
outcom
other
seri
limit
data
suggest
patient
sar
requir
intens
therapi
possibl
transfus
rbc
maintain
hemoglobin
level
mgdl
obviou
limit
studi
includ
small
number
patient
uncontrol
retrospect
design
better
wors
case
literatur
sar
face
previous
unknown
diseas
substanti
mortal
opportun
perform
prospect
random
trial
best
could
done
tri
understand
patholog
induc
viru
design
therapi
might
theoret
help
sar
reemerg
probabl
never
abl
develop
enough
evid
give
clear
guidanc
treatment
best
point
work
retrospect
limit
data
studi
rais
seriou
question
whether
use
ribavirin
sar
patient
wise
sar
infect
clearli
lead
hypoxemia
substanti
number
patient
regardless
caus
anemia
increas
risk
death
hypoxem
patient
given
wellestablish
ae
anemia
patient
treat
ribavirin
drug
use
consider
benefit
treatment
outweigh
risk
pose
druginduc
anemia
benefit
yet
demonstr
patient
infect
sarscov
might
better
forgo
use
ribavirin
sar
patient
